CClinicalTrials.gg
CompletedNCT04824703Updated Apr 30, 2024

Comparative Study Between Liberal and Conservative Oxygen Therapy in Mechanically Ventilated Intensive Care Patients

An interventional study of Oxygen in Oxygen Therapy, sponsored by Aswan University Hospital. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-30.

Sponsored by Aswan University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To assess the benefits and drawbacks of high versus low oxygen therapy on mortality and myocardial function in mechanically ventilated patients

02

Conditions studied

  • Oxygen Therapy

Keywords

  • Oxygen therapy and Mortality
03

In context

Lead sponsor

Aswan University Hospital is the lead sponsor of 95 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • adults aged 18 years or older admitted to ICU and expected to receive mechanical ventilation beyond next calendar day

Exclusion Criteria:

  • inclusion in other trial
  • severe acute respiratory distress syndrome at time of admission
  • acute Chronic obstructive airway disease exacerbation
  • pregnancy
  • Carbon monoxide poisoning
  • Guillain Barre syndrome
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
106 participants (actual)

Study arms

  • Active comparator
    Conservative oxygen therapy

    * Spo2 alarm limit will be set as follow: - upper limit 94% and lower limit 88% * If spo2 \>94% Unless fio2 is 0.21%, decrease fio2 by 0.10% at intervals no longer than 5 minutes till spo2 = 94% * If spo2 within target Decrease fio2 0.05% at intervals no longer than 30 min till fio2 0.21% reached or spo2 = 88 % * If spo2 \< 88 % return to previous spo2 that achieve target spo2. * if an arterial blood gas demonstrate that the PaO2 is \< 60 mmHg FiO2 will increased if clinically appropriate irrespective of the SpO2 reading ( target po2 60-100 mmhg ) * During intubation, airway suction, tracheostomy, bronchoscopy, transportation outside of the ICU for radiological or other investigations or for procedures or operations, other critical situations such as hemodynamic collapse, patients will receive standard (non-study)treatment. * Echocardiography on randomization and at end of the study: we will calculate stroke volume according to Simpson's apical four view

    Drug: Oxygen

  • Placebo comparator
    Liberal oxygen therapy

    * Spo2 target \> 95% * No specific measures will be taken to avoid high fio2 or high po2 * Use of upper alarm limit for spo2 will be prohibited * Echocardiography on randomization and at end of the study: we will calculate stroke volume according to Simpson's apical four view

    Drug: Oxygen

Interventions

  • DrugOxygen

    * Decreasing fraction of inspired oxygen and its effect on mortality and myocardial function * administered by invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1

06

What researchers measure

Primary outcomes

  1. Change in Stroke volume in milliliters

    Volume of blood in milliliters that is ejected from heart each second and measured By Echocardiography

    Time frame: Change from Baseline stroke volume At ICU admission and through study completion An average 6 months

  2. Change in ejection fraction of heart in percentage

    percentage of blood that's pumped out of a filled ventricle with each heartbeat And measured by echocardiography

    Time frame: Change from baseline ejection fraction at icu admission and through study completion An Average 6 months

Secondary outcomes

  1. Acute respiratory distress syndrome

    Acute persistent hypoxia with bilateral lung infiltrate due to non cardiac cause

    Time frame: From icu admission date to icu discharge date an average of 2 weeks

  2. Sepsis

    Systolic blood pressure \< 90 Respiratory rate \> 22 Heart rate \> 100

    Time frame: From icu admission date to icu discharge date an average of 2 weeks

  3. Stroke

    Cerebrovascular accidents

    Time frame: From icu admission date to icu discharge date an average of 2 weeks

  4. Mechanical Ventilator free days

    Days without mechanical ventilation

    Time frame: From icu admission date to icu discharge date an average of 2 weeks

  5. Shock

    Systolic blood pressure \< 90 mmHg

    Time frame: From icu admission date to icu discharge date an average of 2 weeks

  6. Surgery revision

    Surgical re exploration

    Time frame: From icu admission date to icu discharge date an average of 2 weeks

  7. Vasopressor

    Use of vasopressors as norepinephrine and epinephrine

    Time frame: From icu admission date to icu discharge date an average of 2 weeks

  8. ICU stay

    Duration of intensive care stay

    Time frame: From icu admission date to icu discharge date an average of 2 weeks

  9. Hospital stay

    Duration of hospital stay

    Time frame: From icu admission date to icu discharge date an average of 2 weeks

  10. Mortality

    Death of patient

    Time frame: From icu admission date to icu discharge date an average of 2 weeks

07

Study locations

1 site
  • Aswan university hospital
    Aswan, Egypt
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04824703
Lead sponsor
Aswan University Hospital
Responsible party
Ahmed Sayed Mohamed Tammam (Assistant lecturer, Aswan University Hospital) — Principal investigator
First posted
Apr 1, 2021
Start date
Apr 5, 2021
Primary completion
May 5, 2023
Completion
May 11, 2023
Last update
Apr 30, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion